The connection between depression and premature aging now has molecular precision, with potentially transformative implications for treating both conditions. Rather than viewing depression purely as a mental health disorder, this multi-omics analysis positions it as a systemic disease that measurably accelerates cellular aging processes throughout the body and brain. Researchers analyzed protein and epigenetic markers across two large population cohorts—the UK Biobank and Finnish Twin Cohort—finding that individuals with major depressive disorder showed accelerated aging signatures at both systemic and organ-specific levels. The protein-based aging clocks proved more sensitive than epigenetic markers, revealing particularly pronounced effects in brain tissue. Most significantly, the study demonstrated bidirectional causality: depression accelerates biological aging, while accelerated aging increases depression risk. The relationship extends beyond correlation, with proteomic aging acceleration predicting higher risks of Alzheimer's disease, dementia, and mortality among depressed individuals. However, evidence of remission from depressive episodes appeared to attenuate these aging effects, suggesting the process may be partially reversible. This finding represents a paradigm shift in understanding depression's long-term health consequences. The identification of specific protein signatures opens new therapeutic avenues—treatments could potentially target the aging acceleration itself rather than just mood symptoms. For health-conscious adults, this research underscores depression as a serious longevity risk factor requiring prompt, comprehensive treatment. The proteomic aging clocks may eventually serve as biomarkers to monitor treatment effectiveness and guide intervention timing, transforming depression care from sympom management to cellular health optimization.